Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH).
Tumor patients with active cancer and newly diagnosed thromboembolic events are randomised to receive either Rivaroxaban or the standard treatment with low-molecular heparin.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 450 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study
Study Start Date: March 2016
Estimated Primary Completion Date: December 2019
Estimated Study Completion Date: December 2019
- Experimental: Rivaroxaban
- Active Comparator: low-molecular heparine
|Study start date||01 March 2016|
|Actual study completion date||01 December 2019|